4.6 Article

The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+(CD279+) lymphocytes in marrow

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Biophysics

Inhibition of FLT3 in AML: a focus on sorafenib

A. Antar et al.

BONE MARROW TRANSPLANTATION (2017)

Review Cell Biology

T-cell exhaustion in the tumor microenvironment

Y. Jiang et al.

CELL DEATH & DISEASE (2015)

Review Medicine, General & Internal

Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Nestor R. Ramos et al.

JOURNAL OF CLINICAL MEDICINE (2015)

Article Hematology

Acute myeloid leukemia: 2013 update on risk-stratification and management

Elihu H. Estey

AMERICAN JOURNAL OF HEMATOLOGY (2013)

Review Immunology

The mTOR pathway and integrating immune regulation

Stephen P. Cobbold

IMMUNOLOGY (2013)

Editorial Material Oncology

Sorafenib - a small molecule with big promise?

Tamar Tadmor et al.

LEUKEMIA & LYMPHOMA (2010)

Review Biophysics

Management of relapse after allo-SCT for AML and the role of second transplantation

B. N. Savani et al.

BONE MARROW TRANSPLANTATION (2009)

Article Rheumatology

The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications

T. Weichhart et al.

ANNALS OF THE RHEUMATIC DISEASES (2008)

Article Oncology

Potential role of sorafenib in the treatment of acute myeloid leukemia

Shahram Mori et al.

LEUKEMIA & LYMPHOMA (2008)

Review Biotechnology & Applied Microbiology

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

Scott Wilhelm et al.

NATURE REVIEWS DRUG DISCOVERY (2006)

Article Biophysics

Low CXCR4 membrane expression on CD34+ cells characterizes cells mobilized to blood

D Dlubek et al.

BONE MARROW TRANSPLANTATION (2006)